168 related articles for article (PubMed ID: 35939202)
1. STUB1-SMYD2 Axis Regulates Drug Resistance in Glioma cells.
Pan K; Hu B; Wang L; Yuan J; Xu W
J Mol Neurosci; 2022 Sep; 72(9):2030-2044. PubMed ID: 35939202
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of SMYD2 suppresses tumor progression by down-regulating microRNA-125b and attenuates multi-drug resistance in renal cell carcinoma.
Yan L; Ding B; Liu H; Zhang Y; Zeng J; Hu J; Yao W; Yu G; An R; Chen Z; Ye Z; Xing J; Xiao K; Wu L; Xu H
Theranostics; 2019; 9(26):8377-8391. PubMed ID: 31754403
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of SMYD2 protects against cisplatin-induced renal fibrosis and inflammation.
Chen M; Zuo S; Chen S; Li X; Zhang T; Yang D; Zou X; Yang Y; Long H; Peng R; Yuan H; Guo B; Liu L
J Pharmacol Sci; 2023 Sep; 153(1):38-45. PubMed ID: 37524453
[TBL] [Abstract][Full Text] [Related]
4. Critical roles of SMYD2 lysine methyltransferase in mediating renal fibroblast activation and kidney fibrosis.
Liu L; Liu F; Guan Y; Zou J; Zhang C; Xiong C; Zhao TC; Bayliss G; Li X; Zhuang S
FASEB J; 2021 Jul; 35(7):e21715. PubMed ID: 34143514
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological inhibition of SMYD2 protects against cisplatin-induced acute kidney injury in mice.
Cui B; Hou X; Liu M; Li Q; Yu C; Zhang S; Wang Y; Wang J; Zhuang S; Liu F
Front Pharmacol; 2022; 13():829630. PubMed ID: 36046818
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic regulation of SMAD3 by histone methyltransferase SMYD2 promotes lung cancer metastasis.
Kim K; Ryu TY; Jung E; Han TS; Lee J; Kim SK; Roh YN; Lee MS; Jung CR; Lim JH; Hamamoto R; Lee HW; Hur K; Son MY; Kim DS; Cho HS
Exp Mol Med; 2023 May; 55(5):952-964. PubMed ID: 37121971
[TBL] [Abstract][Full Text] [Related]
7. The E3 ubiquitin ligase STUB1 attenuates cell senescence by promoting the ubiquitination and degradation of the core circadian regulator BMAL1.
Ullah K; Chen S; Lu J; Wang X; Liu Q; Zhang Y; Long Y; Hu Z; Xu G
J Biol Chem; 2020 Apr; 295(14):4696-4708. PubMed ID: 32041778
[TBL] [Abstract][Full Text] [Related]
8. SMYD2 promotes tumorigenesis and metastasis of lung adenocarcinoma through RPS7.
Wu L; Kou F; Ji Z; Li B; Zhang B; Guo Y; Yang L
Cell Death Dis; 2021 May; 12(5):439. PubMed ID: 33935284
[TBL] [Abstract][Full Text] [Related]
9. Lysine methyltransferase SMYD2 promotes cyst growth in autosomal dominant polycystic kidney disease.
Li LX; Fan LX; Zhou JX; Grantham JJ; Calvet JP; Sage J; Li X
J Clin Invest; 2017 Jun; 127(7):2751-2764. PubMed ID: 28604386
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
11. The lysine methyltransferase SMYD2 methylates the kinase domain of type II receptor BMPR2 and stimulates bone morphogenetic protein signaling.
Gao S; Wang Z; Wang W; Hu X; Chen P; Li J; Feng X; Wong J; Du JX
J Biol Chem; 2017 Jul; 292(30):12702-12712. PubMed ID: 28588028
[TBL] [Abstract][Full Text] [Related]
12. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
[TBL] [Abstract][Full Text] [Related]
13. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.
Abu-Farha M; Lambert JP; Al-Madhoun AS; Elisma F; Skerjanc IS; Figeys D
Mol Cell Proteomics; 2008 Mar; 7(3):560-72. PubMed ID: 18065756
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
Brown MA; Sims RJ; Gottlieb PD; Tucker PW
Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
[TBL] [Abstract][Full Text] [Related]
15. Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.
Zhang X; Tanaka K; Yan J; Li J; Peng D; Jiang Y; Yang Z; Barton MC; Wen H; Shi X
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17284-9. PubMed ID: 24101509
[TBL] [Abstract][Full Text] [Related]
16. SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes.
Bai HJ; Zhang P; Ma L; Liang H; Wei G; Yang HT
Stem Cells; 2019 Nov; 37(11):1401-1415. PubMed ID: 31348575
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SMYD2 Sensitized Cisplatin to Resistant Cells in NSCLC Through Activating p53 Pathway.
Shang L; Wei M
Front Oncol; 2019; 9():306. PubMed ID: 31106145
[TBL] [Abstract][Full Text] [Related]
18. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
Komatsu S; Ichikawa D; Hirajima S; Nagata H; Nishimura Y; Kawaguchi T; Miyamae M; Okajima W; Ohashi T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Imoto I; Inazawa J; Otsuji E
Br J Cancer; 2015 Jan; 112(2):357-64. PubMed ID: 25321194
[TBL] [Abstract][Full Text] [Related]
20. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
